UNSPSC 51132210: Acetaminophen/butalbital/caffeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132210 Acetaminophen/butalbital/caffeine is a Commodity code that nominally addresses a specific pharmaceutical combination product, but the recent state and local opportunities tagged under it diverge significantly from this narrow scope. Instead, the code is currently capturing a broader range of pharmaceutical and OTC product procurements, including naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local issuing bodies applying this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work being solicited reflects demand for pharmaceutical supply chain management, including product sourcing through authorized wholesalers, compliance with FDA and DSCSA requirements, and inventory management tied to community health initiatives.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; vendors must include shipping and delivery costs, maintain drug-free workplace certification, and comply with E-Verify requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for self-insured state employee plans, seeking vendor experience with direct contracting outside traditional pharmacy benefit manager and wholesaler arrangements. Minnesota's MMCAP issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencara), Cardinal Health, and Morris & Dickson; vendors must supply detailed National Drug Code information, comply with cGMP and DSCSA certification, maintain relationships with at least two authorized wholesalers, and pay a 3 percent administrative fee on all purchases, with pricing evaluated at 75 percent weight.